Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: jelrod3 who wrote (4250)	7/11/1998 5:44:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

All, an old story worth revisiting: For Many, the Viagra Story Turned Out to Be a Sleeper washingtonpost.com

To: jelrod3 who wrote (4250)	7/12/1998 9:05:00 AM
From: Brian P.	Read Replies (1) \| Respond to of 9523

<< The agency is expected to give the drug fast-track review, which could put it on the market by early next year before Merck can submit its clinical results with Vioxx. If that happens, Vioxx may not get fast-track processing-the FDA is reluctant to grant expedited review to drugs that are similar to ones already on the market, says Salomon analyst Heuer....The Pfizer-Searle team could gain an extra six months of market exclusivity if Merck is denied fast review-"easily worth $500 million," says Heuer....>> Do you all think this is a likely scenario? Thanks.